Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tanezumab Dances Through Back Pain Studies With “Acceptable” Safety Answers

Executive Summary

In its latest TANGO trial for chronic lower back pain, Eli Lilly and Pfizer’s tanezumab has shown efficacy at 10 mg, but its 5 mg dose missed the statistically significant mark. Vitally, analysts are encouraged by safety data.

Advertisement

Related Content

Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain
Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?
Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications
Pfizer forced to discontinue more trials for novel pain drug tanezumab

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel